FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Ascend Laboratories Dabigatran Etexilate Recall

Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem…

Ascend Laboratories, LLC · Parsippany, NJ

Risk level
Class II
Reported by FDA
Dec 18, 2024
Recall ID
D-0130-2025
Check your lot numberHow we source this data

Summary

Ascend Laboratories recalled Dabigatran Etexilate starting Dec 12, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0130-2025 on Dec 18, 2024. Reason: CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit. Status: Ongoing.

Why it was recalled

CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit

Product description

Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-475-60

Lot numbers, UPCs & expiration codes

Lot #: 24142192, 24142193, 24142194, Exp. Date April 30, 2026; 24142463, Exp. Date May 31, 2026;

Where it was sold

Nationwide within the United States

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0130-2025
Classification
Class II
Status
Ongoing
Recall initiated
Dec 12, 2024
FDA report date
Dec 18, 2024
Quantity
10,444 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Ascend Laboratories, LLC

Original FDA data

Every field from FDA enforcement report D-0130-2025, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Ongoing
Country
United States
Event ID
95896
Address
339 Jefferson Rd Ste 101
Code information
Lot #: 24142192, 24142193, 24142194, Exp. Date April 30, 2026; 24142463, Exp. Date May 31, 2026;
Postal code
07054-3707
Report date
Dec 18, 2024
Product type
Drugs
Recall number
D-0130-2025
Classification
Class II
Recalling firm
Ascend Laboratories, LLC
Product quantity
10,444 bottles
Reason for recall
CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
Voluntary / mandated
Voluntary: Firm initiated
Product description
Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-475-60
Distribution pattern
Nationwide within the United States
Recall initiation date
Dec 12, 2024
Initial firm notification
Letter
Center classification date
Dec 12, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0130-2025, published Dec 18, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls